Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kuolung Hu

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
JACC. Basic to Translational Science|July 5, 2021
Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 StudiesErin S Morgan, Yvonne Tami, Kuolung Hu, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
Cancer|October 15, 2010
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromesMikkael A Sekeres, Hagop Kantarjian, Pierre Fenaux, et al.
Blood|July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Cancer|April 8, 2014
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopeniaAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaArend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
JACC. Basic to Translational Science|July 5, 2021
Antisense Inhibition of Angiotensinogen With IONIS-AGT-L<sub>Rx</sub>: Results of Phase 1 and Phase 2 StudiesErin S Morgan, Yvonne Tami, Kuolung Hu, et al.
Journal of Hematology & Oncology|November 30, 2012
A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomideEunice S Wang, Roger M Lyons, Richard A Larson, et al.
Cancer|October 15, 2010
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromesMikkael A Sekeres, Hagop Kantarjian, Pierre Fenaux, et al.
Blood|July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapyHagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Cancer|April 8, 2014
Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopeniaAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopeniaHagop Kantarjian, Pierre Fenaux, Mikkael A Sekeres, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaArend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Pageof 2